Treace Medical Concepts, Inc. revised revenue guidance for the year 2023. Treace is raising its full-year 2023 revenue guidance to $191 million to $197 million, which represents approximately 35% to 39% growth over the Company?s 2022 revenue. This compares to the prior full-year 2023 revenue guidance of $190 million to $196 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.48 USD | -6.72% | +6.20% | -57.02% |
29/05 | Treace Medical Concepts Insider Bought Shares Worth $253,475, According to a Recent SEC Filing | MT |
17/05 | North American Morning Briefing : The "Everything -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.02% | 34Cr | |
+75.69% | 1.26TCr | |
-25.24% | 728.94Cr | |
+9.42% | 680.82Cr | |
+18.48% | 566.86Cr | |
-17.19% | 491.45Cr | |
+17.14% | 418.21Cr | |
-21.23% | 386.19Cr | |
-22.54% | 292.38Cr | |
+60.01% | 257.08Cr |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Revises Revenue Guidance for the Year 2023